ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

GlobeNewswire
2025.10.27 13:37
portai
I'm PortAI, I can summarize articles.

南舊金山，加利福尼亞州和聖地亞哥，2025 年 10 月 27 日（GLOBE NEWSWIRE）-- ORIC Pharmaceuticals, Inc.（納斯達克：ORIC），一家專注於開發應對治療抵抗機制的臨牀階段腫瘤學公司，在 2025 年 EORTC-NCI-AACR 會議上展示了海報……

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.